Aethon Therapeutics
Creating neoantigens by design — to transform cancer treatments into cures.
United States · $30.0M raised
- Employees
- 11–50
- Business Model
- B2B
- Website
- aethontx.com
- Total Funding
- $30.0M
- Last Round
- $30.0M Series AJan 2023
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Aethon Therapeutics develops novel anti-drug-peptide conjugate/MHC antibodies using its proprietary HapImmune™ platform to fight drug-resistant cancers. The antibodies work in combination with targeted covalent inhibitors (TCIs) of RAS, EGFR, and other oncogenic mutations, enabling the immune system to recognize and eliminate residual cancer cells. The company was founded in 2022 by venture capital firm ATP and researchers from NYU Langone Health.
Summary
Aethon Therapeutics is a Biotech company based in United States. It has raised $30.0M in total across 1 round, most recently a $30.0M Series A round in Jan 2023. Investors include Apple Tree Partners.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jan 2023
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/aethon-therapeutics"><img src="https://indexed.vc/api/badge/company/aethon-therapeutics" alt="Aethon Therapeutics on Indexed.vc" width="260" height="76" /></a>